Structural neural plasticity evoked by rapid-acting antidepressant interventions
This review (2024) highlights preclinical research from the past 15 years showing that ketamine and psychedelics trigger dendritic spine growth in cortical pyramidal neurons, enhancing neural plasticity. It compares the longitudinal effects of psychoactive drugs, emphasizing rapid-onset and sustained structural plasticity as key features of rapid-acting antidepressants, and discusses gaps in understanding and prospects for other interventions like rTMS.
Abstract
A feature in the pathophysiology of major depressive disorder (MDD), a mood disorder, is the impairment of excitatory synapses in the prefrontal cortex. Intriguingly, different types of treatment with fairly rapid antidepressant effects (within days or a few weeks), such as ketamine, electroconvulsive therapy and non-invasive neurostimulation, seem to converge on enhancement of neural plasticity. However, the forms and mechanisms of plasticity that link antidepressant interventions to the restoration of excitatory synaptic function are still unknown. In this Review, we highlight preclinical research from the past 15 years showing that ketamine and psychedelic drugs can trigger the growth of dendritic spines in cortical pyramidal neurons. We compare the longitudinal effects of various psychoactive drugs on neuronal rewiring, and we highlight rapid onset and sustained time course as notable characteristics for putative rapid-acting antidepressant drugs. Furthermore, we consider gaps in the current understanding of drug-evoked in vivo structural plasticity. We also discuss the prospects of using synaptic remodelling to understand other antidepressant interventions, such as repetitive transcranial magnetic stimulation. Finally, we conclude that structural neural plasticity can provide unique insights into the neurobiological actions of psychoactive drugs and antidepressant interventions.
Research Summary of 'Structural neural plasticity evoked by rapid-acting antidepressant interventions'
Introduction
Dendritic spines are the primary sites of excitatory input onto cortical pyramidal neurons, and their morphology correlates with the presence and strength of excitatory synapses and hence circuit wiring. Liao and colleagues note that although many psychoactive drugs change spine structure after chronic administration, recent longitudinal in vivo optical imaging in rodents has shown that single doses of certain compounds can produce rapid and long-lasting structural remodelling. Drugs highlighted for this property include ketamine and serotonergic psychedelics and analogues, several of which have either established or emerging clinical evidence as rapid-acting antidepressants. This Review sets out to synthesise preclinical work from roughly the past 15 years that tracks drug-evoked structural plasticity in vivo, to compare time courses and persistence across different psychoactive compounds, and to connect these findings to human evidence of synaptic deficits in depression. The authors aim to identify characteristics that distinguish putative rapid-acting antidepressant interventions, to discuss gaps in understanding of in vivo structural plasticity, and to consider translational opportunities for other interventions such as repetitive transcranial magnetic stimulation (TMS).
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Author
- APA Citation
Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C., & Kwan, A. C. (2025). Structural neural plasticity evoked by rapid-acting antidepressant interventions. Nature Reviews Neuroscience, 26(2), 101-114. https://doi.org/10.1038/s41583-024-00876-0
References (13)
Papers cited by this study that are also in Blossom
Shao, L-X,, Liao, C., Gregg, I. et al. · Neuron (2021)
Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)
Lu, J., Tjia, M., Mullen, B. et al. · Molecular Psychiatry (2021)
Abdallah, C. G., Charney, D. S., Duman, R. S. et al. · Neuron (2019)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
De La, M., Revenga, F., Zhu, B. et al. · Cell Reports (2021)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Show all 13 referencesShow fewer
Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)
Reckweg, J., Mason, N. L., van Leeuwen, C. et al. · Frontiers in Pharmacology (2021)
Savalia, N., Shao, L-X,, Kwan, A. C. · Trends in Neuroscience (2021)
Cited By (1)
Papers in Blossom that reference this study
Agnorelli, C., Spriggs, M. J., Godfrey, K. et al. · Preprints (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.